Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA3 | P34903 | 15/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 13/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 13/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 11/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.39 |
| ▸ | PTAFR | P25105 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417353 | 0.89 | GABRA3 (0.67) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL3415181 | 0.85 | GABRA3 (0.56) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL2842188 | 0.78 | GABRG2 (0.81) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL3139904 | 0.78 | GABRA1 (0.47) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL19368389 | 0.76 | GABRA3 (0.65) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL2840548 | 0.75 | GABRA1 (0.56) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL18096788 | 0.75 | GABRA3 (0.61) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL7308306 | 0.75 | GABRA3 (0.62) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL2845678 | 0.74 | GABRA3 (0.74) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL13061667 | 0.69 | GABRA3 (1.00) | GABRA3GABRG2GABRB3GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | GABRA3 5/4885GABRG2 11/4885GABRB3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.